TY - JOUR
T1 - Highlights of the second international conference on "immunotherapy in pediatric oncology"
AU - Capitini, Christian M.
AU - Gottschalk, Stephen
AU - Brenner, Malcolm
AU - Cooper, Laurence J.N.
AU - Handgretinger, Rupert
AU - MacKall, Crystal L.
N1 - Funding Information:
Received 6 June 2011; accepted 9 June 2011. This work was funded by the intramural research program at the National Institutes of Health. Disclaimer. The content of this publication does not necessarily reflect the views of policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. Address correspondence to Christian M. Capitini, MD, National Cancer Institute/NIH, 10 Center Drive, MSC 1104, Bethesda, MD 20892, USA. E-mail: capitinic@mail.nih.gov
PY - 2011/9
Y1 - 2011/9
N2 - The Second International Conference on Immunotherapy in Pediatric Oncology was held in Houston, Texas, USA, October 1112, 2010, to discuss the progress and challenges that have occurred in cutting edge immunotherapeutic strategies currently being developed for pediatric oncology. Major topics included immune targeting of acute lymphoblastic leukemia and pediatric solid tumors, chimeric antigen receptors (CARs) for hematologic malignancies and solid tumors, enhancing graft-versus-leukemia for pediatric cancers, overcoming hurdles of immunotherapy, strategies to active the innate immune system, and moving immunotherapy beyond phase I studies. Significant progress has been made in the last 2 years both in the development of novel immunobiologics such as CARs, and in establishing survival benefits of an anti-GD2 monoclonal antibody in randomized studies. Although there is much excitement going forward, a great deal of laboratory and regulatory challenges lie ahead in improving the efficacy of each of these modalities as well as getting them to patients in a timely and cost-effective fashion. The resulting discussions will hopefully lead to new collaborations and insight for further translational and clinical studies.
AB - The Second International Conference on Immunotherapy in Pediatric Oncology was held in Houston, Texas, USA, October 1112, 2010, to discuss the progress and challenges that have occurred in cutting edge immunotherapeutic strategies currently being developed for pediatric oncology. Major topics included immune targeting of acute lymphoblastic leukemia and pediatric solid tumors, chimeric antigen receptors (CARs) for hematologic malignancies and solid tumors, enhancing graft-versus-leukemia for pediatric cancers, overcoming hurdles of immunotherapy, strategies to active the innate immune system, and moving immunotherapy beyond phase I studies. Significant progress has been made in the last 2 years both in the development of novel immunobiologics such as CARs, and in establishing survival benefits of an anti-GD2 monoclonal antibody in randomized studies. Although there is much excitement going forward, a great deal of laboratory and regulatory challenges lie ahead in improving the efficacy of each of these modalities as well as getting them to patients in a timely and cost-effective fashion. The resulting discussions will hopefully lead to new collaborations and insight for further translational and clinical studies.
KW - HSCT
KW - immunology
KW - immunotherapy
KW - oncology (target therapy)
KW - phase I/II studies
UR - http://www.scopus.com/inward/record.url?scp=80051985900&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80051985900&partnerID=8YFLogxK
U2 - 10.3109/08880018.2011.596615
DO - 10.3109/08880018.2011.596615
M3 - Review article
C2 - 21854215
AN - SCOPUS:80051985900
SN - 0888-0018
VL - 28
SP - 459
EP - 460
JO - Pediatric Hematology and Oncology
JF - Pediatric Hematology and Oncology
IS - 6
ER -